MEIP vs. RDHL, MGTA, SPRO, VTVT, EPRX, HOOK, TPST, GNLX, ACRS, and BNTC
Should you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include RedHill Biopharma (RDHL), Magenta Therapeutics (MGTA), Spero Therapeutics (SPRO), vTv Therapeutics (VTVT), Eupraxia Pharmaceuticals (EPRX), Hookipa Pharma (HOOK), Tempest Therapeutics (TPST), Genelux (GNLX), Aclaris Therapeutics (ACRS), and Benitec Biopharma (BNTC). These companies are all part of the "medical" sector.
RedHill Biopharma (NASDAQ:RDHL) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends.
MEI Pharma has a net margin of 39.06% compared to MEI Pharma's net margin of 0.00%. RedHill Biopharma's return on equity of 48.32% beat MEI Pharma's return on equity.
7.2% of RedHill Biopharma shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 6.8% of RedHill Biopharma shares are held by company insiders. Comparatively, 3.9% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
RedHill Biopharma has a beta of 3.47, indicating that its share price is 247% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.
RedHill Biopharma received 49 more outperform votes than MEI Pharma when rated by MarketBeat users. Likewise, 68.76% of users gave RedHill Biopharma an outperform vote while only 60.87% of users gave MEI Pharma an outperform vote.
MEI Pharma has a consensus price target of $7.00, indicating a potential upside of 144.76%. Given RedHill Biopharma's higher probable upside, analysts plainly believe MEI Pharma is more favorable than RedHill Biopharma.
RedHill Biopharma has higher earnings, but lower revenue than MEI Pharma.
In the previous week, RedHill Biopharma and RedHill Biopharma both had 3 articles in the media. MEI Pharma's average media sentiment score of 0.85 beat RedHill Biopharma's score of 0.29 indicating that RedHill Biopharma is being referred to more favorably in the media.
Summary
RedHill Biopharma beats MEI Pharma on 7 of the 13 factors compared between the two stocks.
Get MEI Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MEI Pharma Competitors List
Related Companies and Tools
